Date: 2011-06-29
Type of information: R&D agreement
Compound: genome engineering tools
Company: Cellectis (France) Pregenen (USA)
Therapeutic area:
Type agreement: research - R&D
Action mechanism:
Disease:
Details: Cellectis has signed a collaboration agreement with Pregenen, a start-up company specialized in the development of new methods for gene repair and innovative approaches in gene therapy. The collaboration agreement between these two companies will allow them to combine their expertise and technological advances to produce improved high-performance Genome engineering tools, most notably Meganucleases and advanced meganuclease vector technologies. The agreement also includes the development of Meganucleases for use in key therapeutic applications.
Financial terms:
Latest news:
